Lv3
346 积分 2023-07-03 加入
Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial
8天前
已完结
Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial
8天前
已完结
支气管哮喘防治指南（2024年版）
21天前
已完结
Sublingual allergen immunotherapy prevents house dust mite inhalant type 2 immunity through dendritic cell-mediated induction of Foxp3+ regulatory T cells
1个月前
已完结
The renaissance of oral tolerance: merging tradition and new insights
1个月前
已完结
New Approaches to Food Allergy Immunotherapy
1个月前
已完结
Current updates in the epidemiology and comorbidities of atopic dermatitis
1个月前
已完结
Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, open, parallel-group study
1个月前
已完结
Efficacy of Subcutaneous, Sublingual and Oral Immunotherapy for Allergens: A Comparative Study
1个月前
已完结
Artemisia annua sublingual immunotherapy in children with seasonal allergic rhinitis
2个月前
已完结
不同流式细胞分析仪检测淋巴亚群的比较研究
5个月前
已撤回
米诺环素对缺血性卒中的神经保护作用
5个月前
已采纳
宁波市大气颗粒物与人群因心脑血管疾病死亡的时间序列研究
5个月前
已采纳
高危急性髓系白血病异基因造血干细胞移植后复发的防治
5个月前
已采纳
老年患者药源性心血管不良反应特点及影响因素
6个月前
已采纳
An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma
1年前
已采纳
An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma
1年前
已驳回
皖公网安备34019202002308
